PTH has a more pronounced effect on vertebral bone mass and biomechanical competence than antiresorptive agents (estrogen and bisphosphonate)—assessed in …
L Mosekilde, CH Søgaard, JE McOsker, TJ Wronski - Bone, 1994 - Elsevier
L Mosekilde, CH Søgaard, JE McOsker, TJ Wronski
Bone, 1994•ElsevierThe aim of the study was to determine the effect of PTH, the antiresorptive agents estrogen
and bisphosphonate (Risedronate), and also the combination of PTH with the antiresorptive
drugs on vertebral bone mass and biomechanical competence in a sexually mature,
ovariectomized rat model. A total of 138 3-month-old Sprague-Dawley rats were randomized
into seven groups:(1) sham operated (control);(2) ovariectomized (OVX);(3) OVX plus
estrogen;(4) OVX plus bisphosphonate [Risedronate (NE)];(5) OVX plus hPTH (1–34);(6) …
and bisphosphonate (Risedronate), and also the combination of PTH with the antiresorptive
drugs on vertebral bone mass and biomechanical competence in a sexually mature,
ovariectomized rat model. A total of 138 3-month-old Sprague-Dawley rats were randomized
into seven groups:(1) sham operated (control);(2) ovariectomized (OVX);(3) OVX plus
estrogen;(4) OVX plus bisphosphonate [Risedronate (NE)];(5) OVX plus hPTH (1–34);(6) …
Abstract
The aim of the study was to determine the effect of PTH, the antiresorptive agents estrogen and bisphosphonate (Risedronate), and also the combination of PTH with the antiresorptive drugs on vertebral bone mass and biomechanical competence in a sexually mature, ovariectomized rat model.
A total of 138 3-month-old Sprague-Dawley rats were randomized into seven groups: (1) sham operated (control); (2) ovariectomized (OVX); (3) OVX plus estrogen; (4) OVX plus bisphosphonate [Risedronate (NE)]; (5) OVX plus hPTH (1–34); (6) OVX plus hPTH (1–34) and estrogen; and, finally, (7) OVX plus hPTH (1–34) and Risedronate.
Treatment regimens were initiated 4 weeks after OVX and were continued for 5 and 15 weeks for each treatment group. Changes in bone mass (ash content) and biomechanical competence were assessed on lumbar vertebral body L4.
The results revealed that the Risedronate-treated OVX animals had a higher vertebral bone mass than the OVX group. hPTH (1–34) on its own had a pronounced anabolic effect and increased bone mass 20–25% and bone strength 70–80% over control levels. Neither combination therapy with estrogen nor with Risedronate provided any further advantage. The combination of PTH with Risedronate, though, seemed to allow a continued increase in both bone mass and strength during the whole treatment period.
The study has shown that in sexually mature but still growing ovariectomized rats, PTH alone has a pronounced anabolic effect on vertebral bone mass and strength which is not further augmented by co-therapy with estrogen, while long-term co-therapy with Risedronate showed a significant sustained increase in bone mass and strength throughout the whole treatment period.
It is concluded that PTH alone or in combination with antiresorptive agents seems a promising therapeutic regimen for postmenopausal osteoporosis.
Elsevier
